{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:55:09Z","timestamp":1790016909217,"version":"4.0.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,4,24]],"date-time":"2013-04-24T00:00:00Z","timestamp":1366761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40256-013-0022-7","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T18:48:57Z","timestamp":1367434137000},"page":"233-250","source":"Crossref","is-referenced-by-count":39,"title":["Antiplatelet and Anticoagulant Therapy for Atherothrombotic Disease: The Role of Current and Emerging Agents"],"prefix":"10.1007","volume":"13","author":[{"given":"Dominick J.","family":"Angiolillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,24]]},"reference":[{"issue":"4","key":"22_CR1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","volume":"123","author":"VL Roger","year":"2011","unstructured":"Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18\u2013209.","journal-title":"Circulation"},{"issue":"4","key":"22_CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/09537100120058739","volume":"12","author":"RF Storey","year":"2001","unstructured":"Storey RF. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Platelets. 2001;12(4):197\u2013209.","journal-title":"Platelets"},{"issue":"1","key":"22_CR3","first-page":"431","volume":"73","author":"EJ Wasserman","year":"2006","unstructured":"Wasserman EJ, Shipley NM. Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability. Mt Sinai J Med. 2006;73(1):431\u20139.","journal-title":"Mt Sinai J Med"},{"issue":"24","key":"22_CR4","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","volume":"357","author":"G Davi","year":"2007","unstructured":"Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"3","key":"22_CR5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI20986","volume":"113","author":"RT Dorsam","year":"2004","unstructured":"Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Investig. 2004;113(3):340\u20135.","journal-title":"J Clin Investig"},{"issue":"1 Suppl","key":"22_CR6","doi-asserted-by":"crossref","first-page":"95S","DOI":"10.1378\/chest.119.1_suppl.95S","volume":"119","author":"JI Weitz","year":"2001","unstructured":"Weitz JI, Hirsh J. New anticoagulant drugs. Chest. 2001;119(1 Suppl):95S\u2013107S.","journal-title":"Chest"},{"issue":"3","key":"22_CR7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/ATVBAHA.107.150474","volume":"28","author":"D Varga-Szabo","year":"2008","unstructured":"Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008;28(3):403\u201312.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"22_CR8","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3324\/haematol.2008.003178","volume":"94","author":"J Rivera","year":"2009","unstructured":"Rivera J, Lozano ML, Navarro-Nunez L, et al. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica. 2009;94(5):700\u201311.","journal-title":"Haematologica"},{"key":"22_CR9","doi-asserted-by":"crossref","unstructured":"Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet. 1997;350(9075):389\u201396.","DOI":"10.1016\/S0140-6736(97)01180-X"},{"issue":"5","key":"22_CR10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1161\/hc0502.103329","volume":"105","author":"LD Fiore","year":"2002","unstructured":"Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105(5):557\u201363.","journal-title":"Circulation"},{"issue":"4","key":"22_CR11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","volume":"143","author":"MB Rothberg","year":"2005","unstructured":"Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005;143(4):241\u201350.","journal-title":"Ann Intern Med"},{"issue":"12","key":"22_CR12","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","volume":"99","author":"S Offermanns","year":"2006","unstructured":"Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res. 2006;99(12):1293\u2013304.","journal-title":"Circ Res"},{"issue":"16","key":"22_CR13","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2165\/11640880-000000000-00000","volume":"72","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012;72(16):2087\u2013116.","journal-title":"Drugs"},{"issue":"3","key":"22_CR14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCINTERVENTIONS.111.966176","volume":"5","author":"JL Ferreiro","year":"2012","unstructured":"Ferreiro JL, Angiolillo DJ. New directions in antiplatelet therapy. Circ Cardiovasc Interv. 2012;5(3):433\u201345.","journal-title":"Circ Cardiovasc Interv"},{"issue":"3 Suppl","key":"22_CR15","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1378\/chest.124.3_suppl.18S","volume":"124","author":"LF Brass","year":"2003","unstructured":"Brass LF. Thrombin and platelet activation. Chest. 2003;124(3 Suppl):18S\u201325S.","journal-title":"Chest"},{"issue":"25","key":"22_CR16","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/j.jacc.2010.09.017","volume":"56","author":"SH Schirmer","year":"2010","unstructured":"Schirmer SH, Baumhakel M, Neuberger HR, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol. 2010;56(25):2067\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"22_CR17","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1213\/ane.0b013e31819bcc9c","volume":"108","author":"KA Tanaka","year":"2009","unstructured":"Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009;108(5):1433\u201346.","journal-title":"Anesth Analg"},{"issue":"14","key":"22_CR18","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/eurheartj\/ehp230","volume":"30","author":"F Werf Van de","year":"2009","unstructured":"Van de Werf F. New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome? Eur Heart J. 2009;30(14):1695\u2013702.","journal-title":"Eur Heart J"},{"issue":"1","key":"22_CR19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V100.1.148","volume":"100","author":"KE Brummel","year":"2002","unstructured":"Brummel KE, Paradis SG, Butenas S, et al. Thrombin functions during tissue factor-induced blood coagulation. Blood. 2002;100(1):148\u201352.","journal-title":"Blood"},{"issue":"8","key":"22_CR20","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1111\/j.1538-7836.2005.01377.x","volume":"3","author":"SR Coughlin","year":"2005","unstructured":"Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3(8):1800\u201314.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"22_CR21","first-page":"1373","volume":"4","author":"MR Lassen","year":"2008","unstructured":"Lassen MR, Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag. 2008;4(6):1373\u201386.","journal-title":"Vasc Health Risk Manag"},{"issue":"3 Suppl","key":"22_CR22","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1378\/chest.124.3_suppl.4S","volume":"124","author":"KG Mann","year":"2003","unstructured":"Mann KG. Thrombin formation. Chest. 2003;124(3 Suppl):4S\u201310S.","journal-title":"Chest"},{"issue":"7329","key":"22_CR23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","unstructured":"Antithrombotic Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71\u201386.","journal-title":"BMJ"},{"issue":"11","key":"22_CR24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med"},{"issue":"20","key":"22_CR25","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med"},{"issue":"7","key":"22_CR26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494\u2013502.","journal-title":"N Engl J Med"},{"issue":"43","key":"22_CR27","doi-asserted-by":"crossref","first-page":"18605","DOI":"10.1073\/pnas.1013309107","volume":"107","author":"I Cornelissen","year":"2010","unstructured":"Cornelissen I, Palmer D, David T, et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc Natl Acad Sci USA. 2010;107(43):18605\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"22_CR28","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/01.CIR.0000146341.63677.3C","volume":"110","author":"S Gruner","year":"2004","unstructured":"Gruner S, Prostredna M, Aktas B, et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Circulation. 2004;110(18):2946\u201351.","journal-title":"Circulation"},{"issue":"11","key":"22_CR29","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","volume":"55","author":"AJ Reininger","year":"2010","unstructured":"Reininger AJ, Bernlochner I, Penz SM, et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol. 2010;55(11):1147\u201358.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"22_CR30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jcin.2011.03.001","volume":"4","author":"DJ Angiolillo","year":"2011","unstructured":"Angiolillo DJ, Ueno M. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations. JACC Cardiovasc Interv. 2011;4(4):411\u20134.","journal-title":"JACC Cardiovasc Interv"},{"issue":"9678","key":"22_CR31","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849\u201360.","journal-title":"Lancet"},{"issue":"8","key":"22_CR32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774\u201382.","journal-title":"Circulation"},{"issue":"10","key":"22_CR33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/eurheartj\/ehm019","volume":"28","author":"SV Rao","year":"2007","unstructured":"Rao SV, Eikelboom JA, Granger CB, et al. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(10):1193\u2013204.","journal-title":"Eur Heart J"},{"issue":"2","key":"22_CR34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.103.2.201","volume":"103","author":"DP Chew","year":"2001","unstructured":"Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb\/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103(2):201\u20136.","journal-title":"Circulation"},{"issue":"9302","key":"22_CR35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","volume":"359","author":"E Boersma","year":"2002","unstructured":"Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359(9302):189\u201398.","journal-title":"Lancet"},{"issue":"1","key":"22_CR36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0735-1097(02)02666-9","volume":"41","author":"E Karvouni","year":"2003","unstructured":"Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb\/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41(1):26\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"22_CR37","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","volume":"295","author":"A Kastrati","year":"2006","unstructured":"Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295(13):1531\u20138.","journal-title":"JAMA"},{"issue":"4","key":"22_CR38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1253\/circj.CJ-09-0982","volume":"74","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74(4):597\u2013607.","journal-title":"Circ J"},{"issue":"3 Suppl","key":"22_CR39","doi-asserted-by":"crossref","first-page":"40A","DOI":"10.1016\/j.amjcard.2008.11.023","volume":"103","author":"DJ Angiolillo","year":"2009","unstructured":"Angiolillo DJ, Bhatt DL, Gurbel PA, et al. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol. 2009;103(3 Suppl):40A\u201351A.","journal-title":"Am J Cardiol"},{"issue":"10","key":"22_CR40","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","volume":"363","author":"SR Mehta","year":"2010","unstructured":"Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930\u201342.","journal-title":"N Engl J Med"},{"issue":"12","key":"22_CR41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/ncpcardio1372","volume":"5","author":"NC Raju","year":"2008","unstructured":"Raju NC, Eikelboom JW, Hirsh J. Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med. 2008;5(12):766\u201380.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"14","key":"22_CR42","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"DJ Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"22_CR43","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0300-8932(10)70010-5","volume":"63","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Ferreiro JL. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev Esp Cardiol. 2010;63(1):60\u201376.","journal-title":"Rev Esp Cardiol"},{"issue":"9749","key":"22_CR44","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","volume":"376","author":"JL Mega","year":"2010","unstructured":"Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312\u20139.","journal-title":"Lancet"},{"issue":"4","key":"22_CR45","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363\u201375.","journal-title":"N Engl J Med"},{"issue":"4","key":"22_CR46","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354\u201362.","journal-title":"N Engl J Med"},{"issue":"8","key":"22_CR47","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2012.11.040","volume":"61","author":"AL Frelinger III","year":"2013","unstructured":"Frelinger AL III, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013;61(8):872\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"22_CR48","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","volume":"301","author":"PM Ho","year":"2009","unstructured":"Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301(9):937\u201344.","journal-title":"JAMA"},{"issue":"1","key":"22_CR49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","volume":"89","author":"DJ Angiolillo","year":"2011","unstructured":"Angiolillo DJ, Gibson CM, Cheng S, et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65\u201374.","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"22_CR50","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jacc.2011.12.024","volume":"59","author":"AL Frelinger III","year":"2012","unstructured":"Frelinger AL III, Lee RD, Mulford DJ, et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012;59(14):1304\u201311.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"22_CR51","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909\u201317.","journal-title":"N Engl J Med"},{"issue":"5","key":"22_CR52","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCULATIONAHA.110.965640","volume":"123","author":"T Simon","year":"2011","unstructured":"Simon T, Steg PG, Gilard M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123(5):474\u201382.","journal-title":"Circulation"},{"key":"22_CR53","unstructured":"Plavix (clopidogrel) [prescribing information]. 2011. Bristol Myers Squibb\/Sanofi Pharmaceutics."},{"issue":"22","key":"22_CR54","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"JP Collet","year":"2012","unstructured":"Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367(22):2100\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"22_CR55","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIR.0b013e318256f1e0","volume":"126","author":"H Jneid","year":"2012","unstructured":"Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF\/AHA focused update of the guideline for the management of patients with unstable angina\/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2012;126(7):875\u2013910.","journal-title":"Circulation"},{"issue":"24","key":"22_CR56","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2011.08.007","volume":"58","author":"GN Levine","year":"2011","unstructured":"Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44\u2013122.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"22_CR57","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"MJ Price","year":"2011","unstructured":"Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097\u2013105.","journal-title":"JAMA"},{"issue":"24","key":"22_CR58","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"D Trenk","year":"2012","unstructured":"Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"9038","key":"22_CR59","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329\u201339.","journal-title":"Lancet"},{"issue":"19","key":"22_CR60","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411\u201320.","journal-title":"JAMA"},{"issue":"9281","key":"22_CR61","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527\u201333.","journal-title":"Lancet"},{"issue":"12","key":"22_CR62","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179\u201389.","journal-title":"N Engl J Med"},{"issue":"10","key":"22_CR63","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","volume":"294","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294(10):1224\u201332.","journal-title":"JAMA"},{"issue":"9497","key":"22_CR64","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"ZM Chen","year":"2005","unstructured":"Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607\u201321.","journal-title":"Lancet"},{"issue":"16","key":"22_CR65","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706\u201317.","journal-title":"N Engl J Med"},{"issue":"19","key":"22_CR66","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2007.03.025","volume":"49","author":"DL Bhatt","year":"2007","unstructured":"Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"9748","key":"22_CR67","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0140-6736(10)61088-4","volume":"376","author":"SR Mehta","year":"2010","unstructured":"Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233\u201343.","journal-title":"Lancet"},{"issue":"10","key":"22_CR68","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","volume":"27","author":"T Jernberg","year":"2006","unstructured":"Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166\u201373.","journal-title":"Eur Heart J"},{"issue":"4","key":"22_CR69","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","volume":"25","author":"JA Jakubowski","year":"2007","unstructured":"Jakubowski JA, Winters KJ, Naganuma H, et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357\u201374.","journal-title":"Cardiovasc Drug Rev"},{"issue":"1","key":"22_CR70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","volume":"29","author":"L Wallentin","year":"2008","unstructured":"Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29(1):21\u201330.","journal-title":"Eur Heart J"},{"issue":"25","key":"22_CR71","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923\u201332.","journal-title":"Circulation"},{"key":"22_CR72","unstructured":"Briefing Information for the February 3, 2009 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. 2009. Food and Drug Administration."},{"issue":"1","key":"22_CR73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ahj.2010.04.022","volume":"160","author":"CT Chin","year":"2010","unstructured":"Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina\/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J. 2010;160(1):16\u201322.","journal-title":"Am Heart J"},{"key":"22_CR74","doi-asserted-by":"crossref","unstructured":"Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012. doi: 10.1056\/NEJMoa1205512 .","DOI":"10.1056\/NEJMoa1205512"},{"issue":"9","key":"22_CR75","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S Husted","year":"2006","unstructured":"Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038\u201347.","journal-title":"Eur Heart J"},{"issue":"25","key":"22_CR76","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET\/OFFSET study. Circulation. 2009;120(25):2577\u201385.","journal-title":"Circulation"},{"key":"22_CR77","unstructured":"AstraZeneca LP. Brilinta (ticagrelor tablets) [prescribing information]. 2013. http:\/\/www1.astrazeneca-us.com\/pi\/brilinta.pdf ."},{"issue":"5","key":"22_CR78","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","volume":"124","author":"KW Mahaffey","year":"2011","unstructured":"Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124(5):544\u201354.","journal-title":"Circulation"},{"key":"22_CR79","unstructured":"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin (PEGASUS). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01225562?term=ticagrelor&rank=6 (2011). Accessed 10 May 2011."},{"key":"22_CR80","unstructured":"A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID). http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01732822?term=ticagrelor&rank=11 (2013). NCT01732822. Accessed 15 Mar 2013."},{"issue":"4","key":"22_CR81","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/fca.10.67","volume":"6","author":"M Ueno","year":"2010","unstructured":"Ueno M, Rao SV, Angiolillo DJ. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 2010;6(4):445\u201353.","journal-title":"Future Cardiol"},{"issue":"1","key":"22_CR82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ahj.2010.04.008","volume":"160","author":"S Leonardi","year":"2010","unstructured":"Leonardi S, Rao SV, Harrington RA, et al. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). Am Heart J. 2010;160(1):65\u201372.","journal-title":"Am Heart J"},{"issue":"3","key":"22_CR83","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1161\/CIRCINTERVENTIONS.111.964197","volume":"5","author":"RC Welsh","year":"2012","unstructured":"Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012;5(3):336\u201346.","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"22_CR84","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCINTERVENTIONS.111.965608","volume":"5","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Welsh RC, Trenk D, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012;5(3):347\u201356.","journal-title":"Circ Cardiovasc Interv"},{"issue":"8","key":"22_CR85","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1586\/erc.10.90","volume":"8","author":"M Ueno","year":"2010","unstructured":"Ueno M, Ferreiro JL, Angiolillo DJ. Update on the clinical development of cangrelor. Expert Rev Cardiovasc Ther. 2010;8(8):1069\u201377.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"3","key":"22_CR86","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","volume":"307","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265\u201374.","journal-title":"JAMA"},{"issue":"24","key":"22_CR87","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318\u201329.","journal-title":"N Engl J Med"},{"issue":"24","key":"22_CR88","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330\u201341.","journal-title":"N Engl J Med"},{"issue":"5","key":"22_CR89","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","volume":"163","author":"S Leonardi","year":"2012","unstructured":"Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012;163(5):768\u201376.","journal-title":"Am Heart J"},{"key":"22_CR90","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013. doi: 10.1056\/NEJMoa1300815 .","journal-title":"N Engl J Med"},{"issue":"12","key":"22_CR91","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.91.12.2961","volume":"91","author":"JJ Cook","year":"1995","unstructured":"Cook JJ, Sitko GR, Bednar B, et al. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation. 1995;91(12):2961\u201371.","journal-title":"Circulation"},{"issue":"2","key":"22_CR92","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1124\/jpet.102.042663","volume":"304","author":"CK Derian","year":"2003","unstructured":"Derian CK, Damiano BP, Addo MF, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther. 2003;304(2):855\u201361.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2\u20133","key":"22_CR93","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(03)01973-3","volume":"473","author":"Y Kato","year":"2003","unstructured":"Kato Y, Kita Y, Hirasawa-Taniyama Y, et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur J Pharmacol. 2003;473(2\u20133):163\u20139.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"22_CR94","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1073\/pnas.0610188104","volume":"104","author":"ER Vandendries","year":"2007","unstructured":"Vandendries ER, Hamilton JR, Coughlin SR, et al. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci USA. 2007;104(1):288\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"22_CR95","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehp504","volume":"31","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31(1):17\u201328.","journal-title":"Eur Heart J"},{"issue":"12","key":"22_CR96","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1161\/STROKEAHA.112.670604","volume":"43","author":"M Lee","year":"2012","unstructured":"Lee M, Saver JL, Hong KS, et al. Risk of intracranial hemorrhage with protease-activated receptor-1 antagonists. Stroke. 2012;43(12):3189\u201395.","journal-title":"Stroke"},{"issue":"10","key":"22_CR97","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2012.04869.x","volume":"10","author":"D Capodanno","year":"2012","unstructured":"Capodanno D, Bhatt DL, Goto S, et al. Safety and efficacy of protease-activated receptor-1 antagonists in patients with coronary artery disease: a meta-analysis of randomized clinical trials. J Thromb Haemost. 2012;10(10):2006\u201315.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"22_CR98","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","volume":"51","author":"S Chackalamannil","year":"2008","unstructured":"Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51(11):3061\u20134.","journal-title":"J Med Chem"},{"issue":"3","key":"22_CR99","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ahj.2009.06.027","volume":"158","author":"DA Morrow","year":"2009","unstructured":"Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J. 2009;158(3):335\u201341.","journal-title":"Am Heart J"},{"issue":"3","key":"22_CR100","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ahj.2009.07.001","volume":"158","author":"The TRA*CER Executive and Steering Committees","year":"2009","unstructured":"The TRA*CER Executive and Steering Committees. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. Am Heart J. 2009;158(3):327\u201334.","journal-title":"Am Heart J"},{"issue":"9667","key":"22_CR101","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(09)60230-0","volume":"373","author":"RC Becker","year":"2009","unstructured":"Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373(9667):919\u201328.","journal-title":"Lancet"},{"issue":"2","key":"22_CR102","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5551\/jat.3038","volume":"17","author":"S Goto","year":"2010","unstructured":"Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010;17(2):156\u201364.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"22_CR103","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"P Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20\u201333.","journal-title":"N Engl J Med"},{"issue":"15","key":"22_CR104","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"DA Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404\u201313.","journal-title":"N Engl J Med"},{"issue":"17","key":"22_CR105","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1161\/CIRCULATIONAHA.111.021733","volume":"123","author":"F Werf Van de","year":"2011","unstructured":"Van de Werf F. Inhibitors of the platelet thrombin receptor will they live up to their promises? Circulation. 2011;123(17):1833\u20135.","journal-title":"Circulation"},{"key":"22_CR106","unstructured":"Kogushi M, Kobayashi H, Matsuoka T, et al. Anti-thrombotic and bleeding time effects of e555, an orally active protease-activated receptor-1 antagonist, in guinea pigs (abstract). Circulation. 2003;108:280."},{"issue":"4","key":"22_CR107","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/fca.12.35","volume":"8","author":"F Rollini","year":"2012","unstructured":"Rollini F, Tello-Montoliu A, Angiolillo DJ. Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. Future Cardiol. 2012;8(4):503\u201311.","journal-title":"Future Cardiol"},{"issue":"1","key":"22_CR108","first-page":"111","volume":"102","author":"VL Serebruany","year":"2009","unstructured":"Serebruany VL, Kogushi M, Dastros-Pitei D, et al. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost. 2009;102(1):111\u20139.","journal-title":"Thromb Haemost"},{"issue":"21","key":"22_CR109","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/eurheartj\/ehq320","volume":"31","author":"S Goto","year":"2010","unstructured":"Goto S, Ogawa H, Takeuchi M, et al. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J. 2010;31(21):2601\u201313.","journal-title":"Eur Heart J"},{"issue":"17","key":"22_CR110","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","volume":"123","author":"ML O\u2019Donoghue","year":"2011","unstructured":"O\u2019Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011;123(17):1843\u201353.","journal-title":"Circulation"},{"issue":"17","key":"22_CR111","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1161\/CIRCULATIONAHA.110.001404","volume":"123","author":"SD Wiviott","year":"2011","unstructured":"Wiviott SD, Flather MD, O\u2019Donoghue ML, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation. 2011;123(17):1854\u201363.","journal-title":"Circulation"},{"issue":"3","key":"22_CR112","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1476-5381.2009.00555.x","volume":"159","author":"JM Siller-Matula","year":"2010","unstructured":"Siller-Matula JM, Krumphuber J, Jilma B. Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol. 2010;159(3):502\u201317.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"22_CR113","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1474-4422(10)70038-7","volume":"9","author":"GJ Hankey","year":"2010","unstructured":"Hankey GJ, Eikelboom JW. Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol. 2010;9(3):273\u201384.","journal-title":"Lancet Neurol"},{"issue":"7","key":"22_CR114","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/CIRCULATIONAHA.106.177292","volume":"114","author":"V Fuster","year":"2006","unstructured":"Fuster V, Ryden LE, Cannom DS, et al. ACC\/AHA\/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257\u2013354.","journal-title":"Circulation"},{"issue":"2","key":"22_CR115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(89)80689-8","volume":"87","author":"CS Landefeld","year":"1989","unstructured":"Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87(2):144\u201352.","journal-title":"Am J Med"},{"issue":"11","key":"22_CR116","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197\u2013206.","journal-title":"JAMA"},{"key":"22_CR117","unstructured":"Phase III Acute Coronary Syndrome (APPRAISE-2). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00831441?term=apixaban&rank=15 (2010). Accessed 9 May 2011."},{"key":"22_CR118","unstructured":"Effect of Otamixaban Versus Unfractionated Heparin\u00a0+\u00a0Eptifibatide in Patients With Unstable Angina\/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy (TAO). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01076764?term=otamixaban&rank=1 (2012). Accessed 9 May 2011."},{"issue":"5","key":"22_CR119","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","volume":"161","author":"CM Gibson","year":"2011","unstructured":"Gibson CM, Mega JL, Burton P, et al. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome. Am Heart J. 2011;161(5):815\u201321.","journal-title":"Am Heart J"},{"issue":"22","key":"22_CR120","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781\u20139.","journal-title":"Eur Heart J"},{"issue":"1","key":"22_CR121","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1160\/TH09-06-0361","volume":"103","author":"KW Phillips","year":"2010","unstructured":"Phillips KW, Ansell J. The clinical implications of new oral anticoagulants: will the potential advantages be achieved? Thromb Haemost. 2010;103(1):34\u20139.","journal-title":"Thromb Haemost"},{"issue":"2","key":"22_CR122","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ahj.2010.10.022","volume":"161","author":"TJ Povsic","year":"2011","unstructured":"Povsic TJ, Cohen MG, Mehran R, et al. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. Am Heart J. 2011;161(2):261\u20138.","journal-title":"Am Heart J"},{"issue":"22","key":"22_CR123","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","volume":"119","author":"JH Alexander","year":"2009","unstructured":"Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119(22):2877\u201385.","journal-title":"Circulation"},{"issue":"9683","key":"22_CR124","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","volume":"374","author":"JL Mega","year":"2009","unstructured":"Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374(9683):29\u201338.","journal-title":"Lancet"},{"key":"22_CR125","unstructured":"Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J. 2011;32(16):1968\u201376, 1976a."},{"issue":"9692","key":"22_CR126","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(09)61454-9","volume":"374","author":"MS Sabatine","year":"2009","unstructured":"Sabatine MS, Antman EM, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2009;374(9692):787\u201395.","journal-title":"Lancet"},{"issue":"9386","key":"22_CR127","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","volume":"362","author":"L Wallentin","year":"2003","unstructured":"Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362(9386):789\u201397.","journal-title":"Lancet"},{"issue":"8","key":"22_CR128","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"1","key":"22_CR129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9\u201319.","journal-title":"N Engl J Med"},{"issue":"13","key":"22_CR130","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","volume":"295","author":"S Yusuf","year":"2006","unstructured":"Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295(13):1519\u201330.","journal-title":"JAMA"},{"issue":"14","key":"22_CR131","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","volume":"354","author":"S Yusuf","year":"2006","unstructured":"Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464\u201376.","journal-title":"N Engl J Med"},{"issue":"6","key":"22_CR132","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ahj.2012.10.001","volume":"164","author":"PG Steg","year":"2012","unstructured":"Steg PG, Mehta SR, Pollack CV Jr, et al. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. Am Heart J. 2012;164(6):817\u201324.","journal-title":"Am Heart J"},{"key":"22_CR133","doi-asserted-by":"crossref","unstructured":"Povsic TJ, Vavalle JP, Aberle LH, et al. A phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J. 2012; Epub ahead of print.","DOI":"10.1093\/eurheartj\/ehs232"},{"key":"22_CR134","unstructured":"Regado Biosciences. http:\/\/www.regadobio.com\/index.php\/2012\/12\/regado-biosciences-inc-secures-51-million-series-e-financing\/ (2013). Accessed 18 Mar 2013."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0022-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-013-0022-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-013-0022-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:24Z","timestamp":1559489304000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-013-0022-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,24]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["22"],"URL":"https:\/\/doi.org\/10.1007\/s40256-013-0022-7","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,24]]}}}